Weight Management · 4,731.3 g/mol (C221H342N46O68) · 39 amino acids
Research Chemical - Not for Human Use
Best price per mg
$5.65/mg
with discount code · market North America
- 3
- Vendors
- 6
- Lab tests
- 100
- best rating
Compare Retatrutide prices per mg from 3 vendors, with published certificates of analysis and lab results where available.
Read purity and measured quantity separately: a high purity percentage does not establish the amount in a vial. Match each result to its sample, date and original report.
Description
Retatrutide (LY3437943) is an experimental peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. A receptor receives signals; an agonist activates it. Clinical trials study its effects on body weight and blood sugar. Study results do not verify the quality or effects of supplier products.
Quick Facts
- Category
- Weight Management
- Molecular Weight
- 4,731.3 g/mol (C221H342N46O68)
- Half-Life
- ~6 days (human phase 1b; Urva et al., 2022)
- CAS Number
- 2381089-83-2
- Amino Acids
- 39
- Storage
- -20°C lyophilized; 2-8°C reconstituted
- Solubility
- Soluble in sterile water or bacteriostatic water
A CAS number uniquely identifies a chemical substance.
g/mol describes mass per mole; Da describes the mass of a single molecule. A vendor’s mg value is the mass in the offered package.
Amino acids are the building blocks of a peptide; the count gives their number.
Independent tests of Retatrutide
Bought as a customer, analysed by an independent laboratory.
The score covers its measured scoring axes only. Open the report for unmeasured or non-comparable attributes; it does not establish sterility, safety or efficacy.
- 82passed
RC Peptides, 82 passed
Janoshik Analytical · November 11, 2026
Reported measurements: LCMS screening, Retatrutide, Purity, Endotoxin, As, Cd, Pb, Hg.
- 92passed
Avellon Peptides, 92 passed
Janoshik Analytical · September 11, 2026
Reported measurements: LCMS screening, As, Cd, Pb, Hg, Endotoxin, Retatrutide, Purity.
- 20not passed
BioLab Shop, 20 not passed
Janoshik Analytical · September 2, 2026
Reported measurements: Endotoxin, Retatrutide, Purity, Comment, As, Cd, Pb, Hg.
Offers
3 vendorsfrom $5.65/mg with code
A Retatrutide certificate of analysis (COA) describes a tested sample. Match the batch identifier, laboratory and methods to the offer. Vendor COAs and tests commissioned by ChemVerify are separate evidence.
Look up a batch COACertificates of analysis for Retatrutide
8 vendors publish third-party certificates of analysis for Retatrutide. 49 published reports in total. Best reported purity per vendor: 99.73%–99.89%.
- Peptidwerk
Janoshik Analytical · July 24, 2026
99.89%COA from Peptidwerk - Elyvera (Europeptides)
Janoshik Analytical · June 5, 2026
- RC Peptides
Janoshik Analytical · May 6, 2026
99.81%COA from RC Peptides - Licensed Peptides
Vanguard Laboratory · January 29, 2026
- Particle Peptides
Liquilabs s.r.o. · March 2, 2026
Research Summary
Phase 2 obesity and type 2 diabetes trials were published in 2023. Phase 3 TRIUMPH-1 results followed on 29 September 2026. The trials used defined investigational material; they do not establish the identity, quality or effects of supplier products listed here.
Mechanism of Action
Retatrutide activates GIP, GLP-1 and glucagon receptors involved in metabolic signalling. Activating three receptors does not by itself prove superiority over medicines that activate one or two.
Studies and chemical references
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Jastreboff AM, Kaplan LM, Davies MJ, et al. (2026) – New England Journal of Medicine
TRIUMPH-1: randomised phase 3 trial in 2,339 adults with obesity without diabetes over 80 weeks. Published 29 September 2026; gastrointestinal events were the most common adverse events.
DOI: 10.1056/nejmoa2604169Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. (2023) – New England Journal of Medicine
Randomised phase 2 trial in 338 adults: average weight change at 48 weeks was −24.2% in the highest studied group versus −2.1% with placebo. Group averages do not predict individual outcomes.
DOI: 10.1056/nejmoa2301972Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J, Frias J, Jastreboff AM, et al. (2023) – The Lancet
Phase 2 trial in adults with type 2 diabetes examining HbA1c, a measure of average blood sugar, and body weight. Placebo and dulaglutide were comparators.
DOI: 10.1016/s0140-6736(23)01053-xLY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. (2022) – Lancet (London, England)
A human phase 1b trial reported an approximate half-life of 6 days. This is a study estimate for the defined investigational molecule, not a measured property of supplier material.
DOI: 10.1016/s0140-6736(22)02033-5Retatrutide: substance identity and systematic chemical name (NOP2Y096GV)
NCATS; USAN Council nomenclature (2026) – NCATS Global Substance Registration System
The systematic name defines 39 residues with Aib at positions 2 and 20, α-methyl-L-leucine at position 13, Lys17 linked through one AEEA and γ-glutamyl spacer to a C20 diacid, and a C-terminal amide. Aib is α-aminoisobutyric acid. The registry backbone alone omits these modifications and is not the complete molecule.
NCATS Global Substance Registration SystemRetatrutide: molecular formula and molar mass (D12430)
KEGG (2026) – KEGG DRUG
C221H342N46O68 gives an average molar mass of 4731.3 g/mol when rounded to one decimal place. This calculated peptide-moiety value excludes counterions and is not a batch measurement.
KEGG DRUGStudies cited are from published peer-reviewed literature. Referenced for laboratory research context only.
Known Research Compound Interactions
Based on published preclinical research literature
For laboratory research reference only. Not for human consumption. Interaction data derived from preclinical studies and receptor binding profiles. Always consult primary literature for specific research protocols.
Interaction assessments based on receptor binding affinity, signaling pathway analysis, and published preclinical data. For laboratory research use only. Not for human consumption.
Molecular Information
Sequence, synonyms, structure
Molecular Weight
4,731.3 g/mol (C221H342N46O68)
Stated Purity
≥98.0%
Half-Life
~6 days (human phase 1b; Urva et al., 2022)
The stated purity is a specification, not a measured result for a particular batch. Check the corresponding analysis report for the measured value.
Amino Acid Sequence
Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-αMeLeu-Leu-Asp-Lys-Lys(AEEA-γGlu-C20 diacid)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2Also Known As
For laboratory research use only. Not for human consumption.
